Waldheim Pharmazeutika's (Austria) HIV-2 confirmatory well on its way through FDA
This article was originally published in Clinica
Executive Summary
Waldheim Pharmazeutika (Austria) says the US FDA has accepted Product and Establishment Licence Applications for its HIV-2 confirmatory immunofluorescence assay, Fluorognost HIV-2 IFA. "In spite of its huge review burden, the FDA Center of Biologics has sent the filing letter very quickly, and without requesting any further information at this point," said Dr Hermann Mucke, managing director of Waldheim's Diagnostics Division. "We believe that the Agency wants an approved HIV-2 confirmatory test out on the US market as soon as possible."
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.